• IR Case Studies

Companies frequently contact us with a specific objective in mind, such as broadening their
shareholder base, securing analyst coverage or leveraging a year of significant clinical milestones.
Using our expertise and relationships, we develop and launch a comprehensive IR program.

The following are a few significant examples that demonstrate our approach to IR and the results we achieve.

Phase 3 Data For Drug With Mixed History

IR Challenge/Opportunity:

Company A went public two years after announcing negative Phase 3 results for its lead product candidate. Post-IPO, the Company had a limited number of shareholders, a mixed reputation on Wall Street and pending Phase 3 data for the same product in a new indication. Stern IR was retained initially to enhance visibility and awareness in advance of the announcement.

View Case Study
Small-Cap Company With Limited Visibility

IR Challenge/Opportunity:

Company B was in the process of rebuilding and refocusing its pipeline and had only a single research analyst whose coverage no longer fit with the Company’s portfolio. Stern IR was retained initially to help them build a new following of research analysts knowledgeable in the Company’s area of expertise to initiate coverage.

View Case Study
Early-Stage Biotech IPO

IR Challenge/Opportunity:

Company C had a novel discovery platform, premiere scientists, and a strong management team. Stern IR was retained initially to ensure they would have a successful IPO, during a time when later-stage stories were favored over preclinical platform companies as IPO candidates, to create a more stable shareholder base specifically looking to add investors with longer term horizons.

View Case Study
Maintaining Visibility Post-IPO

IR Challenge/Opportunity:

Company D was a development-stage industrial biotech company that had recently completed a very successful IPO in a shaky overall market. Stern IR was responsible for heavily ramping up the IR program, to help maintain the visibility the Company had achieved through the IPO process, to get more investors into the stock and to keep its existing shareholders once the lockup expired.

View Case Study
Investor Targeting Following New Product Launch

IR Challenge/Opportunity:

Company E was a mid-cap biotechnology company that had launched a new product within the last twelve months. The product’s launch was very successful and had captured the attention of momentum, event and other “fast money” investors. While the increased trading activity created liquidity, it also exacerbated share price volatility. Company E wanted to create a more stable shareholder base specifically looking to add investors with longer term horizons.

View Case Study